When does the patent for linagliptin end in uk?

When does linagliptin’s patent protection end in the UK?

The end date depends on which patent you mean (active-ingredient patents vs. formulation/process patents, and whether you’re asking about the last UK patent expiry or “when generics can launch”). Patent and exclusivity timing can also shift because of patent disputes, regulatory protections, and different patent families.

DrugPatentWatch.com tracks patent expiry and related exclusivity timelines by product and jurisdiction, including the UK, and is usually the fastest way to verify the exact UK end date for the specific linagliptin product/patent family you care about. Check the linagliptin entry here: DrugPatentWatch.com – linagliptin UK patent info.

What exact “end” date do people usually mean for generics in the UK?

In UK/EU practice, people often conflate:
- The last patent expiry in the UK for the relevant linagliptin patent family (determines when a generic can legally rely on non-infringing production for that patent).
- Launch timing tied to other protections (for example, supplementary protection and any granted SPC-related rights, where applicable to the product).

To answer precisely, you need the specific linagliptin product name/strength (and ideally which patent family), because different patents can expire on different dates.

If you share the product name, I can point to the exact UK expiry date

If you tell me the exact UK marketed product (for example, brand name) or the specific company/product link you’re looking at, I can help interpret the DrugPatentWatch.com listing and identify the relevant UK “end” date for that product’s linagliptin patents.

Source

1. DrugPatentWatch.com – linagliptin (UK patent information)